Loading…

Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors

Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydr...

Full description

Saved in:
Bibliographic Details
Published in:Archiv der Pharmazie (Weinheim) 2020-05, Vol.353 (5), p.e2000005-n/a
Main Authors: Zhu, Junjie, Wang, Ziqian, Guo, Zongwei, Zhang, Xiaodong, Song, Ting, Guo, Yafei, Ji, Tong, Zhang, Zhichao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713
cites cdi_FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713
container_end_page n/a
container_issue 5
container_start_page e2000005
container_title Archiv der Pharmazie (Weinheim)
container_volume 353
creator Zhu, Junjie
Wang, Ziqian
Guo, Zongwei
Zhang, Xiaodong
Song, Ting
Guo, Yafei
Ji, Tong
Zhang, Zhichao
description Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. Research on structure–activity relationship resulted in a new derivative B4 that is capable of occupying both the p2 and p4 more deeply and completely than A1, with Ki values determined by fluorescence polarization assay (FPAs) improving to 0.31 μM for Bcl‐2 and 0.16 μM for Mcl‐1. Furthermore, B4 exhibited selective lethality on cancer cells over normal cells. It showed stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line and killed an Mcl‐1‐dependent cell line which is resistant to ABT‐199 treatment. Optimization of the previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) resulted in a new derivative B4 that is capable of occupying both the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1 more deeply and completely than A1. B4 shows selective lethality on cancer cells over normal cells and stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line.
doi_str_mv 10.1002/ardp.202000005
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2393984454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2393984454</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713</originalsourceid><addsrcrecordid>eNqFkLlOAzEURS0EIiHQUiJLtJnE6ywlhFUKArG1lscLmWgyE-wxKB2fwDfyJUxICCWvea849z7pAHCI0QAjRIbS6fmAIIKWw7dAF3OCI4ZTtg26iMY8igmlHbDn_bQlKCJ8F3QowQmPCe-C54fGBdUEZ74-PnPpjYba-OKl6kO_qJpJe_s-lJWG5k2WQTZFXcHawlNVtgEyvPnZGOogS1hUkyIvmtr5fbBjZenNwXr3wNPF-ePoKhrfXl6PTsaRognlUaYst9SqhGsa55inWnGbxYkyzDCmLcutzLHJE8SpYiRJU2m1QqlMOaZZgmkPHK96565-DcY3YloHV7UvBaEZzVLGOGupwYpSrvbeGSvmrphJtxAYiaVGsdQoNhrbwNG6NuQzozf4r7cWyFbAe1GaxT914uT-7O6v_BtrtoEk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2393984454</pqid></control><display><type>article</type><title>Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors</title><source>Wiley</source><creator>Zhu, Junjie ; Wang, Ziqian ; Guo, Zongwei ; Zhang, Xiaodong ; Song, Ting ; Guo, Yafei ; Ji, Tong ; Zhang, Zhichao</creator><creatorcontrib>Zhu, Junjie ; Wang, Ziqian ; Guo, Zongwei ; Zhang, Xiaodong ; Song, Ting ; Guo, Yafei ; Ji, Tong ; Zhang, Zhichao</creatorcontrib><description>Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. Research on structure–activity relationship resulted in a new derivative B4 that is capable of occupying both the p2 and p4 more deeply and completely than A1, with Ki values determined by fluorescence polarization assay (FPAs) improving to 0.31 μM for Bcl‐2 and 0.16 μM for Mcl‐1. Furthermore, B4 exhibited selective lethality on cancer cells over normal cells. It showed stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line and killed an Mcl‐1‐dependent cell line which is resistant to ABT‐199 treatment. Optimization of the previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) resulted in a new derivative B4 that is capable of occupying both the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1 more deeply and completely than A1. B4 shows selective lethality on cancer cells over normal cells and stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line.</description><identifier>ISSN: 0365-6233</identifier><identifier>EISSN: 1521-4184</identifier><identifier>DOI: 10.1002/ardp.202000005</identifier><identifier>PMID: 32175625</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>anticancer activities ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Bcl‐2/Mcl‐1 dual inhibitor ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Dose-Response Relationship, Drug ; Drug Design ; Drug Screening Assays, Antitumor ; HEK293 Cells ; Humans ; Molecular Docking Simulation ; Molecular Structure ; Myeloid Cell Leukemia Sequence 1 Protein - antagonists &amp; inhibitors ; Phenalenes - chemical synthesis ; Phenalenes - chemistry ; Phenalenes - pharmacology ; Proto-Oncogene Proteins c-bcl-2 - antagonists &amp; inhibitors ; Structure-Activity Relationship</subject><ispartof>Archiv der Pharmazie (Weinheim), 2020-05, Vol.353 (5), p.e2000005-n/a</ispartof><rights>2020 Deutsche Pharmazeutische Gesellschaft</rights><rights>2020 Deutsche Pharmazeutische Gesellschaft.</rights><rights>2020 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713</citedby><cites>FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713</cites><orcidid>0000-0002-2774-2384</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32175625$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Junjie</creatorcontrib><creatorcontrib>Wang, Ziqian</creatorcontrib><creatorcontrib>Guo, Zongwei</creatorcontrib><creatorcontrib>Zhang, Xiaodong</creatorcontrib><creatorcontrib>Song, Ting</creatorcontrib><creatorcontrib>Guo, Yafei</creatorcontrib><creatorcontrib>Ji, Tong</creatorcontrib><creatorcontrib>Zhang, Zhichao</creatorcontrib><title>Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors</title><title>Archiv der Pharmazie (Weinheim)</title><addtitle>Arch Pharm (Weinheim)</addtitle><description>Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. Research on structure–activity relationship resulted in a new derivative B4 that is capable of occupying both the p2 and p4 more deeply and completely than A1, with Ki values determined by fluorescence polarization assay (FPAs) improving to 0.31 μM for Bcl‐2 and 0.16 μM for Mcl‐1. Furthermore, B4 exhibited selective lethality on cancer cells over normal cells. It showed stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line and killed an Mcl‐1‐dependent cell line which is resistant to ABT‐199 treatment. Optimization of the previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) resulted in a new derivative B4 that is capable of occupying both the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1 more deeply and completely than A1. B4 shows selective lethality on cancer cells over normal cells and stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line.</description><subject>anticancer activities</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Bcl‐2/Mcl‐1 dual inhibitor</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Design</subject><subject>Drug Screening Assays, Antitumor</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Molecular Docking Simulation</subject><subject>Molecular Structure</subject><subject>Myeloid Cell Leukemia Sequence 1 Protein - antagonists &amp; inhibitors</subject><subject>Phenalenes - chemical synthesis</subject><subject>Phenalenes - chemistry</subject><subject>Phenalenes - pharmacology</subject><subject>Proto-Oncogene Proteins c-bcl-2 - antagonists &amp; inhibitors</subject><subject>Structure-Activity Relationship</subject><issn>0365-6233</issn><issn>1521-4184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkLlOAzEURS0EIiHQUiJLtJnE6ywlhFUKArG1lscLmWgyE-wxKB2fwDfyJUxICCWvea849z7pAHCI0QAjRIbS6fmAIIKWw7dAF3OCI4ZTtg26iMY8igmlHbDn_bQlKCJ8F3QowQmPCe-C54fGBdUEZ74-PnPpjYba-OKl6kO_qJpJe_s-lJWG5k2WQTZFXcHawlNVtgEyvPnZGOogS1hUkyIvmtr5fbBjZenNwXr3wNPF-ePoKhrfXl6PTsaRognlUaYst9SqhGsa55inWnGbxYkyzDCmLcutzLHJE8SpYiRJU2m1QqlMOaZZgmkPHK96565-DcY3YloHV7UvBaEZzVLGOGupwYpSrvbeGSvmrphJtxAYiaVGsdQoNhrbwNG6NuQzozf4r7cWyFbAe1GaxT914uT-7O6v_BtrtoEk</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Zhu, Junjie</creator><creator>Wang, Ziqian</creator><creator>Guo, Zongwei</creator><creator>Zhang, Xiaodong</creator><creator>Song, Ting</creator><creator>Guo, Yafei</creator><creator>Ji, Tong</creator><creator>Zhang, Zhichao</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-2774-2384</orcidid></search><sort><creationdate>202005</creationdate><title>Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors</title><author>Zhu, Junjie ; Wang, Ziqian ; Guo, Zongwei ; Zhang, Xiaodong ; Song, Ting ; Guo, Yafei ; Ji, Tong ; Zhang, Zhichao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>anticancer activities</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Bcl‐2/Mcl‐1 dual inhibitor</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Design</topic><topic>Drug Screening Assays, Antitumor</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Molecular Docking Simulation</topic><topic>Molecular Structure</topic><topic>Myeloid Cell Leukemia Sequence 1 Protein - antagonists &amp; inhibitors</topic><topic>Phenalenes - chemical synthesis</topic><topic>Phenalenes - chemistry</topic><topic>Phenalenes - pharmacology</topic><topic>Proto-Oncogene Proteins c-bcl-2 - antagonists &amp; inhibitors</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Junjie</creatorcontrib><creatorcontrib>Wang, Ziqian</creatorcontrib><creatorcontrib>Guo, Zongwei</creatorcontrib><creatorcontrib>Zhang, Xiaodong</creatorcontrib><creatorcontrib>Song, Ting</creatorcontrib><creatorcontrib>Guo, Yafei</creatorcontrib><creatorcontrib>Ji, Tong</creatorcontrib><creatorcontrib>Zhang, Zhichao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Archiv der Pharmazie (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Junjie</au><au>Wang, Ziqian</au><au>Guo, Zongwei</au><au>Zhang, Xiaodong</au><au>Song, Ting</au><au>Guo, Yafei</au><au>Ji, Tong</au><au>Zhang, Zhichao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors</atitle><jtitle>Archiv der Pharmazie (Weinheim)</jtitle><addtitle>Arch Pharm (Weinheim)</addtitle><date>2020-05</date><risdate>2020</risdate><volume>353</volume><issue>5</issue><spage>e2000005</spage><epage>n/a</epage><pages>e2000005-n/a</pages><issn>0365-6233</issn><eissn>1521-4184</eissn><abstract>Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. Research on structure–activity relationship resulted in a new derivative B4 that is capable of occupying both the p2 and p4 more deeply and completely than A1, with Ki values determined by fluorescence polarization assay (FPAs) improving to 0.31 μM for Bcl‐2 and 0.16 μM for Mcl‐1. Furthermore, B4 exhibited selective lethality on cancer cells over normal cells. It showed stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line and killed an Mcl‐1‐dependent cell line which is resistant to ABT‐199 treatment. Optimization of the previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) resulted in a new derivative B4 that is capable of occupying both the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1 more deeply and completely than A1. B4 shows selective lethality on cancer cells over normal cells and stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32175625</pmid><doi>10.1002/ardp.202000005</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2774-2384</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0365-6233
ispartof Archiv der Pharmazie (Weinheim), 2020-05, Vol.353 (5), p.e2000005-n/a
issn 0365-6233
1521-4184
language eng
recordid cdi_proquest_journals_2393984454
source Wiley
subjects anticancer activities
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Apoptosis
Apoptosis - drug effects
Bcl‐2/Mcl‐1 dual inhibitor
Cell Line, Tumor
Cell Proliferation - drug effects
Dose-Response Relationship, Drug
Drug Design
Drug Screening Assays, Antitumor
HEK293 Cells
Humans
Molecular Docking Simulation
Molecular Structure
Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors
Phenalenes - chemical synthesis
Phenalenes - chemistry
Phenalenes - pharmacology
Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors
Structure-Activity Relationship
title Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A41%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structure%E2%80%90based%20design,%20synthesis,%20and%20evaluation%20of%20Bcl%E2%80%902/Mcl%E2%80%901%20dual%20inhibitors&rft.jtitle=Archiv%20der%20Pharmazie%20(Weinheim)&rft.au=Zhu,%20Junjie&rft.date=2020-05&rft.volume=353&rft.issue=5&rft.spage=e2000005&rft.epage=n/a&rft.pages=e2000005-n/a&rft.issn=0365-6233&rft.eissn=1521-4184&rft_id=info:doi/10.1002/ardp.202000005&rft_dat=%3Cproquest_cross%3E2393984454%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2393984454&rft_id=info:pmid/32175625&rfr_iscdi=true